Takeaways: Health Canada has authorized PrUpgolyv (golimumab injection), giving Canada its first Simponi biosimilar and further extending JAMP Pharma’s BioJAMP immunolo...
Takeaways VUEWAY should help Bracco win share in Canada’s MRI contrast market by offering radiology departments a lower‑gadolinium option that still delivers high‑quality images, which is increa...
Takeaways: Cysklar gives Canada’s small cystinosis community a dedicated, easy‑to‑use cysteamine eye‑drop option for corneal crystals, strengthening Leadiant’s rare‑disease ...
Takeaways: Neffy creates a new, needle‑free niche in Canada’s anaphylaxis market that should boost overall epinephrine use and take share from traditional auto‑injectors, especially among ...
Takeaways: AstraZeneca deepens its Saphnelo franchise in Canada by adding a self‑administered SC autoinjector on top of IV, improving convenience and persistency in a chronic, mostly f...
Takeaways: Empaveli’s C3G/IC‑MPGN nod makes Sobi/Apellis the first movers in complement‑mediated kidney disease in Canada, turning a ~700‑patient ultra‑rare population into a high‑value, pr...
Takeaways: Apotex’s Denoza biosimilar gives Canada a home‑grown denosumab option, intensifying price and tender pressure on Amgen’s Prolia in a market with 2.3M osteoporosis ...
Takeaways: Health Canada’s CTA clearance positions Affinia among the first wave of next‑gen cardiac gene therapy players, using a bespoke AAV capsid to go after genetically defined BAG...
Takeaways: This tie-up effectively turns WELL’s cardiologist network into an on‑demand, paid “virtual read” service layered on top of AliveCor’s at‑home ECG hardware and AI, direc...
Takeaways: CLOBIVIS modestly strengthens Apotex’s position in Canada’s post‑cataract segment and helps it move up the value chain in eye care beyond pure generics. In marke...
